These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Petersen KR Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723 [TBL] [Abstract][Full Text] [Related]
8. [Contraceptives and the liver]. Schmid M Leber Magen Darm; 1981 Sep; 11(5):216-26. PubMed ID: 7300550 [TBL] [Abstract][Full Text] [Related]
9. Thrombosis--perspective on a major side effect of oral contraceptives. Briggs M Med J Aust; 1976 Jul; 2(1):30. PubMed ID: 979789 [TBL] [Abstract][Full Text] [Related]
10. [Combined contraceptives and cardiovascular risk]. Belaisch J; Hommais-loufrani B Contracept Fertil Sex (Paris); 1987 Dec; 15(12 Suppl):1-8. PubMed ID: 12315199 [TBL] [Abstract][Full Text] [Related]
11. Thrombotic disorders associated with pregnancy and the pill. Tooke JE; McNicol GP Clin Haematol; 1981 Jun; 10(2):613-30. PubMed ID: 7032788 [TBL] [Abstract][Full Text] [Related]
12. [New aspects on thrombosis and roral contraception]. Astedt B Lakartidningen; 1975 Feb; 72(7):585-6. PubMed ID: 1113573 [TBL] [Abstract][Full Text] [Related]
13. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Tanis BC; Rosendaal FR Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494 [TBL] [Abstract][Full Text] [Related]
14. Thrombophilic mechanisms of OCs. Comp PC Int J Fertil Womens Med; 1997; Suppl 1():170-6. PubMed ID: 9168376 [TBL] [Abstract][Full Text] [Related]
15. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323 [TBL] [Abstract][Full Text] [Related]
16. [Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives]. Bauersachs R; Lindhoff-Last E; Ehrly AM; Kuhl H Zentralbl Gynakol; 1996; 118(5):262-70. PubMed ID: 8701622 [TBL] [Abstract][Full Text] [Related]
17. Thrombosis--perspective on a major side effect of oral contraceptives. Briggs M Med J Aust; 1976 Aug; 2(9):356. PubMed ID: 995021 [TBL] [Abstract][Full Text] [Related]
18. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Pabinger I; Schneider B Thromb Haemost; 1994 May; 71(5):548-52. PubMed ID: 8091378 [TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives in 1984. Chapler EK Iowa Med; 1984 Oct; 74(10):439-40, 442. PubMed ID: 6490338 [TBL] [Abstract][Full Text] [Related]
20. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Santamaría A; Mateo J; Oliver A; Menéndez B; Souto JC; Borrell M; Soria JM; Tirado I; Fontcuberta J Haematologica; 2001 Sep; 86(9):965-71. PubMed ID: 11532625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]